Acadia Healthcare Touts Faster Bed Ramp, Reaffirms 2026 Outlook, Eyes Positive Free Cash Flow

Acadia Healthcare (NASDAQ:ACHC) executives used an investor conference appearance to outline operational priorities, discuss recent financial results and guidance, and address topics including payer dynamics, bed ramp-up, and medical malpractice and legal expenses.

Company overview and strategic priorities

Chief Executive Officer Debbie Osteen opened with a high-level overview of Acadia’s footprint and service mix. She said the company generated $3.3 billion in revenue for the full year of 2025 and treats 84,000 patients a day, up from 70,000 when she previously left the company. Acadia operates 277 facilities across 40 states.

Osteen described Acadia as a “pure play” behavioral health provider with diversified service lines, including acute facilities, specialty services (primarily substance use and eating disorders), residential treatment centers for children and adolescents, and 178 comprehensive treatment center (CTC) outpatient locations focused on medication-assisted treatment.

She also pointed to payer and geographic diversification, noting that 57% of payers are Medicaid across service lines and that no single state represents more than 15% of revenue.

Osteen said her focus in returning to the CEO role is to build a strong company centered on excellence in patient care while also creating shareholder value. She laid out four key areas of focus:

• Patient care: building on outcome measures already implemented, publishing outcomes, and continuing improvements in safety and quality.
• Volume: ramping the 2,500 beds added over the last three years and bringing new beds online more efficiently.
• Operational excellence: strengthening payer relationships, maintaining capital discipline, and managing expenses.
• Workforce and talent: recruiting, retaining, and training staff, while evaluating organizational support needs to better align corporate resources with facility operations.

Bed additions and ramp-up plans

Osteen emphasized that Acadia has made significant investments in bed additions and technology and that her main focus for the year is “execution” to realize the value of those investments. She said Acadia has added 2,500 new beds over the last three years and expects 400–600 beds to come online in 2026. She said her goal is to ramp those beds faster than prior additions, improve access, and support facility teams with the right staffing and leadership structure.

In the Q&A portion, Osteen characterized expansion beds at existing facilities as having historically stronger returns than de novo builds, in part because existing overhead can be leveraged. She added that construction costs have increased across project types, including expansions, joint venture builds, and de novo projects.

Financial results and 2026 outlook

Chief Financial Officer Todd Young, who said he has served as CFO since late October, reviewed Acadia’s recent earnings release. Young said the company delivered Q4 revenue and adjusted EBITDA in line with expectations. He also highlighted 3.1% same-store volume growth in Q4, which he described as an acceleration from Q3.

For 2026, Young reiterated guidance of:

• Revenue: $3.37 billion to $3.45 billion
• Adjusted EBITDA: $575 million to $610 million
• Same-facility growth: 0% to 1%

Young said same-facility growth guidance reflects an estimated 350 basis point headwind from a New York Medicaid determination that patients would no longer be allowed to receive treatment in facilities outside New York state. He said Acadia has a large number of specialty facilities in Pennsylvania that had treated patients from New York.

Young also discussed cash flow expectations, saying growth capital expenditures are expected to decline substantially as facility build-outs slow. He cited an expected more than $300 million reduction in growth CapEx from 2025 to 2026, with further declines expected in 2027 as projects are completed. He said that shift supports a projection of positive free cash flow in 2026, which he said should help leverage over time.

Young also described an embedded earnings opportunity tied to filling the newly added capacity, stating the company believes the recently added beds, along with beds coming online in 2026, create an estimated $200 million adjusted EBITDA opportunity as occupancy rises.

Medical malpractice trends and monitoring

In response to questions about medical malpractice and legal costs, Young said Acadia recorded $115 million of medical malpractice expense in 2025 and guided to $100 million to $110 million in 2026. He attributed the year-over-year decline to a significant accrual increase taken in Q4 for cases already on the books, which he said management believes brought accruals to an appropriate level.

Young said insurance dynamics have also shifted, noting that three years ago the company carried insurance for cases above $3 million, while the threshold has moved to $15 million, changing the risk profile. He said he reviews actuarial assumptions and case data monthly, tracking claims and settlements to reduce the likelihood of “Q4 surprises.”

Osteen connected malpractice risk to incident prevention, stating that Acadia is using technology and a quality infrastructure to monitor facility-level indicators in real time. She said the company can now review daily facility performance across “50 measures,” which she tied to identifying and reducing incidents that can lead to claims. She also emphasized training and accountability for staff directly interacting with patients.

Payers, outpatient care, and the CTC business

On payer pressure, Osteen said she does not view it as uniform across markets and said the company’s approach is to be constructive and collaborative while demonstrating value through outcomes. She also discussed how some “enlightened” payers may place value on outcome improvements and risk reduction, including metrics such as readmissions, though she acknowledged the broader challenge of defining and benchmarking behavioral health quality measures.

Osteen said follow-up after discharge depends on the program and that some specialty facilities include patient touchpoints after discharge. She also said the company has focused on partial hospitalization and outpatient services as part of a continuum of care, while emphasizing that secure settings remain necessary for patients who are suicidal or homicidal.

Asked about the CTC “methadone” business, Osteen said she does not view it differently than she did previously and reiterated her view that methadone is “the gold standard.” She characterized the segment as requiring low capital to grow and being less labor intensive than acute settings, and said the company believes it still has growth potential given ongoing demand. She added that the company would be open to “another way” to bring value to shareholders, but said management currently likes the business and views it as part of the continuum of care.

In an audience question about state concentration, Osteen said historical acquisitions created clusters in certain markets and that the company evaluates bed need data, reimbursement, staffing availability, and regulatory considerations when deciding where to expand, noting that certificate-of-need dynamics can affect acute expansion decisions while outpatient clinics can be easier to add.

About Acadia Healthcare (NASDAQ:ACHC)

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.